



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

- Name of Inspector from whom received : Laldusangi Hauhnar, (Asst. Drugs Inspector)
Mamit District: Mamit, Pin- 796441
- Serial No. and date of Inspector's memorandum : B.17011/12/09-CMO (M)/DRUGS/135 , 08-APR-2026
- Number of Sample : MD08/135
- Date of receipt : 20-APR-2026
- Names of drugs purporting to be contained in the sample : Prednisolone Dispersible Tablets 10 Mg (CDL)
(Wysolone DT 10)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2026-27/0204	GUW/LS/2026-27/177	ML7375	May-2025 Apr-2027	NA	Pfizer Limited, Plot No.L-137, Phase III-A, Verna Industrial Estate, Verna, Goa 403722

6. Condition of seals on : Seals were intact & identical to the
[the packet or on portion of sample or container] specimen impression of the seal received
from Drugs Inspector

7. Result of test or analysis with protocols or test or analysis applied : Please see below
Date of Testing : From 11-Jun-2026 To 18-Jun-2026

COMPOSITION : Each Uncoated Dispersible Tablet Contains Prednisolone IP 10 Mg

Protocol Applied : Manufacturers Specification

Sr No.	Test Name	Result	Limits
1	Description	White, round, flat, scored on one surface, having engraved "10" on other surface, uncoated tablets, in blister pack.	NA
2	Identification	Gives positive test for Prednisolone.	NA
3	Average Weight	0.1114 g	NA
4	Test For Disintegration	Complies. (Time taken for disintegration 12 seconds)	NMT 3 minutes
5	Uniformity of dispersion	Complies.	NA

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
-------	-----------------	-------	-------	------------	--------	--------------------

1	Prednisolone	10.6 mg/Tablet	10 mg/Tablet	106	90 % to 110 %	Manufacturers Specification
---	--------------	----------------	-----------------	-----	---------------	-----------------------------

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per Manufacturers Specification in respect of test performed.

Date: 01-JUL-2026

GOVERNMENT ANALYST

Rinku Kalita
Rinku Kalita
Government Analyst
R.D.T.L., Guwahati-22

-----END OF REPORT-----

